Cargando…

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study

BACKGROUND: Neutralizing antibodies (NAbs) against Interferon beta (IFNβ) are reported to be associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to quantify the contribution of NAbs to the sub-optimal response of IFNβ treatment. METHODS: We studied the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sbardella, Emilia, Tomassini, Valentina, Gasperini, Claudio, Bellomi, Francesca, Cefaro, Luca Ausili, Morra, Vincenzo Brescia, Antonelli, Guido, Pozzilli, Carlo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770509/ https://www.ncbi.nlm.nih.gov/pubmed/19825153 http://dx.doi.org/10.1186/1471-2377-9-54

Ejemplares similares

Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data
por: Moccia, Marcello, et al.
Publicado: (2021)

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
por: Moccia, Marcello, et al.
Publicado: (2020)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

Evidence of Impaired Brain Activity Balance after Passive Sensorimotor Stimulation in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2013)

IN VITRO ASSESSMENT OF THE BIOLOGIC ACTIVITY OF INTERFERON BETA FORMULATIONS USED FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
por: Scagnolari, Carolina, et al.
Publicado: (2014)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT®) in Parkinson’s disease
por: Marchese, Maria Raffaella, et al.
Publicado: (2022)

Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10
por: Moccia, Marcello, et al.
Publicado: (2019)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
por: Prosperini, Luca, et al.
Publicado: (2011)

Proportion of Dementia Explained by Five Key Factors in Jamaica
por: Ashby-Mitchell, Kimberly, et al.
Publicado: (2020)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

A Comprehensive Review on Copemyl(®)
por: Annovazzi, Pietro, et al.
Publicado: (2017)

Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl(®)
por: Annovazzi, Pietro, et al.
Publicado: (2018)

The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence
por: Tomassini, Valentina, et al.
Publicado: (2016)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Proportion of dementia in Australia explained by common modifiable risk factors
por: Ashby-Mitchell, Kimberly, et al.
Publicado: (2017)

Correction to: Oropharyngeal Dysphagia After Hospitalization for COVID-19 Disease: Our Screening Results
por: Marchese, Maria Rafaella, et al.
Publicado: (2021)

Oropharyngeal Dysphagia After Hospitalization for COVID-19 Disease: Our Screening Results
por: Marchese, Maria Raffaella, et al.
Publicado: (2021)

Homeostasis as a proportional–integral control system
por: Veen, Lennaert van, et al.
Publicado: (2020)

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
por: Manceau, Philippe, et al.
Publicado: (2014)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients
por: Sbardella, Emilia, et al.
Publicado: (2013)

Estimating proportions of explained variance: a comparison of whole genome subsets
por: Aslibekyan, Stella, et al.
Publicado: (2014)

Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE
por: Gómez-Bañuelos, Eduardo, et al.
Publicado: (2023)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

Similarities and differences between multiple sclerosis and type 1 diabetes
por: Pozzilli, Valeria, et al.
Publicado: (2021)

High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19
por: Scordio, Mirko, et al.
Publicado: (2022)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
por: Gavasso, Sonia, et al.
Publicado: (2014)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Hypothesis to explain the disparity in the proportion of liver metastases between appendiceal and colorectal cancer
por: Cristaudo, Adam T., et al.
Publicado: (2022)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
por: van Beers, Miranda M. C., et al.
Publicado: (2011)

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
por: Lugaresi, Alessandra, et al.
Publicado: (2012)

Treatment of SARS with human interferons
por: Antonelli, Guido, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_j8cqr9fckmgeq6rpoq856h41ue